Biotech · Public company · Winchester, MA, US
Synlogic, Inc.
Ticker SYBX · SEC CIK 0001527599
Track this companyFree. Adds Synlogic, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials100 recruiting or active
Pipeline programs12From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availableNo recent cash burn filed
Pipeline12
- SYNB1934v1Phase 3 · PhenylketonuriaClinicalTrials.gov · fetched Nov 12, 2026
- SYNB1020Phase 2 · CirrhosisClinicalTrials.gov · fetched Nov 12, 2026
- SYNB1618Phase 2 · PhenylketonuriaClinicalTrials.gov · fetched Nov 12, 2026
- SYNB1934Phase 2 · PhenylketonuriaClinicalTrials.gov · fetched Nov 12, 2026
- AtezolizumabPhase 1 · Metastatic Solid NeoplasmClinicalTrials.gov · fetched Nov 12, 2026
- SYNB1020Phase 1 · Healthy VolunteerClinicalTrials.gov · fetched Nov 12, 2026
- SYNB1353Phase 1 · HomocystinuriaClinicalTrials.gov · fetched Nov 12, 2026
- SYNB1618Phase 1 · HealthyClinicalTrials.gov · fetched Nov 12, 2026
- SYNB1891Phase 1 · Metastatic Solid NeoplasmClinicalTrials.gov · fetched Nov 12, 2026
- SYNB1934Phase 1 · HealthyClinicalTrials.gov · fetched Nov 12, 2026
- SYNB8802Phase 1 · HealthyClinicalTrials.gov · fetched Nov 12, 2026
- SYNB8802v1Phase 1 · Enteric HyperoxaluriaClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials10
- Efficacy and Safety of SYNB1934 in Patients With PKU (SYNPHENY-3)PHASE3 · TERMINATED · started Jul 5, 2023ClinicalTrials.gov NCT05764239 · fetched Nov 12, 2026
- Safety, Tolerability and Pharmacodynamics of SYNB1353 in Healthy Adult VolunteersPHASE1 · COMPLETED · started Jul 7, 2022ClinicalTrials.gov NCT05462132 · fetched Nov 12, 2026
- Safety, Tolerability, and Pharmacodynamics of SYNB8802v1 in Subjects With History of Gastric Bypass Surgery or Short-bowel SyndromeEARLY_PHASE1 · COMPLETED · started Mar 29, 2022ClinicalTrials.gov NCT05377112 · fetched Nov 12, 2026
- Safety and Tolerability of SYNB1934 in Healthy Adult VolunteersPHASE1 · COMPLETED · started Jul 2, 2021ClinicalTrials.gov NCT04984525 · fetched Nov 12, 2026
- Safety and Tolerability of SYNB8802 in Healthy Adult Volunteers and Adult Subjects With Enteric HyperoxaluriaPHASE1 · COMPLETED · started Nov 4, 2020ClinicalTrials.gov NCT04629170 · fetched Nov 12, 2026
- Efficacy and Safety of SYNB1618 and SYNB1934 in Adult Patients With PhenylketonuriaPHASE2 · COMPLETED · started Aug 25, 2020ClinicalTrials.gov NCT04534842 · fetched Nov 12, 2026
- Safety and Tolerability of SYNB1891 Injection Alone or in Combination With Atezolizumab in Adult ParticipantsPHASE1 · TERMINATED · started Dec 12, 2019ClinicalTrials.gov NCT04167137 · fetched Nov 12, 2026
- Safety and Tolerability of SYNB1618 in Healthy Adult Volunteers and Adult Subjects With PhenylketonuriaPHASE1_PHASE2 · COMPLETED · started Apr 17, 2018ClinicalTrials.gov NCT03516487 · fetched Nov 12, 2026
- Safety, Tolerability and Pharmacodynamics of SYNB1020PHASE1_PHASE2 · TERMINATED · started Mar 19, 2018ClinicalTrials.gov NCT03447730 · fetched Nov 12, 2026
- Safety and Tolerability of SYNB1020-CP-001PHASE1 · COMPLETED · started Jun 16, 2017ClinicalTrials.gov NCT03179878 · fetched Nov 12, 2026
SEC filings12
- 10-Q · 10-QSEC EDGAR · filed Aug 11, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Jul 29, 2026 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed May 14, 2026 · fetched Nov 12, 2026
- 10-K/A · 10-K/ASEC EDGAR · filed Apr 30, 2026 · fetched Nov 12, 2026
- 10-K · 10-KSEC EDGAR · filed Mar 12, 2026 · fetched Nov 12, 2026
- 8-K/A · 8-K/ASEC EDGAR · filed Jan 29, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Jan 20, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Dec 16, 2025 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Nov 26, 2025 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed Nov 13, 2025 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed Aug 7, 2025 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed May 8, 2025 · fetched Nov 12, 2026